Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38


The Vasopressin 1b Receptor Antagonist A-988315 Blocks Stress Effects on the Retrieval of Object-Recognition Memory.

Barsegyan A, Atsak P, Hornberger WB, Jacobson PB, van Gaalen MM, Roozendaal B.

Neuropsychopharmacology. 2015 Jul;40(8):1979-89. doi: 10.1038/npp.2015.48. Epub 2015 Feb 11.


Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis.

Malek S, Sample SJ, Schwartz Z, Nemke B, Jacobson PB, Cozzi EM, Schaefer SL, Bleedorn JA, Holzman G, Muir P.

BMC Vet Res. 2012 Oct 4;8:185. doi: 10.1186/1746-6148-8-185.


Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.

Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, Salyers A, Gomez E, Simler G, Lewis LG, Gauvin D, Baker S, Pai M, Tovcimak A, Brown J, Komater V, Fox GB, Decker MW, Jacobson PB, Gopalakrishnan M, Lee CH, Honore P.

Biochem Pharmacol. 2011 Oct 15;82(8):967-76. doi: 10.1016/j.bcp.2011.05.007. Epub 2011 May 17.


Acute inhibition of 11beta-hydroxysteroid dehydrogenase type-1 improves memory in rodent models of cognition.

Mohler EG, Browman KE, Roderwald VA, Cronin EA, Markosyan S, Scott Bitner R, Strakhova MI, Drescher KU, Hornberger W, Rohde JJ, Brune ME, Jacobson PB, Rueter LE.

J Neurosci. 2011 Apr 6;31(14):5406-13. doi: 10.1523/JNEUROSCI.4046-10.2011.


Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice.

Yang R, Wilcox DM, Haasch DL, Jung PM, Nguyen PT, Voorbach MJ, Doktor S, Brodjian S, Bush EN, Lin E, Jacobson PB, Collins CA, Landschulz KT, Trevillyan JM, Rondinone CM, Surowy TK.

J Biol Chem. 2007 Aug 3;282(31):22765-74. Epub 2007 Jun 5.


Hepatic knockdown of stearoyl-CoA desaturase 1 via RNA interference in obese mice decreases lipid content and changes fatty acid composition.

Xu H, Wilcox D, Nguyen P, Voorbach M, Smith H, Brodjian S, Suhar T, Reilly RM, Jacobson PB, Collins CA, Landschulz K, Surowy TK.

Front Biosci. 2007 May 1;12:3781-94.


Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.

Rohde JJ, Pliushchev MA, Sorensen BK, Wodka D, Shuai Q, Wang J, Fung S, Monzon KM, Chiou WJ, Pan L, Deng X, Chovan LE, Ramaiya A, Mullally M, Henry RF, Stolarik DF, Imade HM, Marsh KC, Beno DW, Fey TA, Droz BA, Brune ME, Camp HS, Sham HL, Frevert EU, Jacobson PB, Link JT.

J Med Chem. 2007 Jan 11;50(1):149-64.


Parallel strategies for the preparation and selection of liver-targeted glucocorticoid receptor antagonists.

Backes BJ, Hamilton GL, Nguyen P, Wilcox D, Fung S, Wang J, Grynfarb M, Goos-Nilsson A, Jacobson PB, von Geldern TW.

Bioorg Med Chem Lett. 2007 Jan 1;17(1):40-4. Epub 2006 Oct 5.


Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile.

Xu H, Wilcox D, Nguyen P, Voorbach M, Suhar T, Morgan SJ, An WF, Ge L, Green J, Wu Z, Gimeno RE, Reilly R, Jacobson PB, Collins CA, Landschulz K, Surowy T.

Biochem Biophys Res Commun. 2006 Oct 13;349(1):439-48. Epub 2006 Aug 22.


Selective antagonism of the hepatic glucocorticoid receptor reduces hepatic glucose production.

Edgerton DS, Jacobson PB, Opgenorth TJ, Zinker B, Beno D, von Geldern T, Ohman L, Scott M, Neal D, Cherrington AD.

Metabolism. 2006 Sep;55(9):1255-62.


Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.

Xin Z, Serby MD, Zhao H, Kosogof C, Szczepankiewicz BG, Liu M, Liu B, Hutchins CW, Sarris KA, Hoff ED, Falls HD, Lin CW, Ogiela CA, Collins CA, Brune ME, Bush EN, Droz BA, Fey TA, Knourek-Segel VE, Shapiro R, Jacobson PB, Beno DW, Turner TM, Sham HL, Liu G.

J Med Chem. 2006 Jul 27;49(15):4459-69.


Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice.

Bush EN, Shapiro R, Brune ME, Knourek-Segel VE, Droz BA, Fey T, Lin E, Jacobson PB.

Endocrine. 2006 Apr;29(2):375-81.


2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists.

Serby MD, Zhao H, Szczepankiewicz BG, Kosogof C, Xin Z, Liu B, Liu M, Nelson LT, Kaszubska W, Falls HD, Schaefer V, Bush EN, Shapiro R, Droz BA, Knourek-Segel VE, Fey TA, Brune ME, Beno DW, Turner TM, Collins CA, Jacobson PB, Sham HL, Liu G.

J Med Chem. 2006 Apr 20;49(8):2568-78.


Distinctions and contradistinctions between antiobesity histamine H(3) receptor (H (3)R) antagonists compared to cognition-enhancing H (3) receptor antagonists.

Hancock AA, Bitner RS, Krueger KM, Otte S, Nikkel AL, Fey TA, Bush EN, Dickinson RW, Shapiro R, Knourek-Segel V, Droz BA, Brune ME, Jacobson PB, Cowart MD, Esbenshade TA.

Inflamm Res. 2006 Apr;55 Suppl 1:S42-4. No abstract available.


Delivery of RNAi reagents in murine models of obesity and diabetes.

Wilcox DM, Yang R, Morgan SJ, Nguyen PT, Voorbach MJ, Jung PM, Haasch DL, Lin E, Bush EN, Opgenorth TJ, Jacobson PB, Collins CA, Rondinone CM, Surowy T, Landschulz KT.

J RNAi Gene Silencing. 2006 Nov 29;3(1):225-36.


Rapamycin analogs with reduced systemic exposure.

Wagner R, Mollison KW, Liu L, Henry CL, Rosenberg TA, Bamaung N, Tu N, Wiedeman PE, Or Y, Luly JR, Lane BC, Trevillyan J, Chen YW, Fey T, Hsieh G, Marsh K, Nuss M, Jacobson PB, Wilcox D, Carlson RP, Carter GW, Djuric SW.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5340-3. Epub 2005 Sep 26.


Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.

Link JT, Sorensen B, Patel J, Grynfarb M, Goos-Nilsson A, Wang J, Fung S, Wilcox D, Zinker B, Nguyen P, Hickman B, Schmidt JM, Swanson S, Tian Z, Reisch TJ, Rotert G, Du J, Lane B, von Geldern TW, Jacobson PB.

J Med Chem. 2005 Aug 11;48(16):5295-304.


Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy.

Hancock AA, Diehl MS, Fey TA, Bush EN, Faghih R, Miller TR, Krueger KM, Pratt JK, Cowart MD, Dickinson RW, Shapiro R, Knourek-Segel VE, Droz BA, McDowell CA, Krishna G, Brune ME, Esbenshade TA, Jacobson PB.

Inflamm Res. 2005 Apr;54 Suppl 1:S27-9. No abstract available.


Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes.

Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, Fey T, Goos-Nilsson A, Grynfarb M, Barkhem T, Marsh K, Beno DW, Nga-Nguyen B, Kym PR, Link JT, Tu N, Edgerton DS, Cherrington A, Efendic S, Lane BC, Opgenorth TJ.

J Pharmacol Exp Ther. 2005 Jul;314(1):191-200. Epub 2005 Mar 22.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk